Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Diabetes. Nov 15, 2020; 11(11): 514-526
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.514
Table 3 Changes in key endpoints from baseline to week 24 of patients in different change of waist-to-height ratio groups treated with acarbose
High ΔWHtRLower ΔWHtRP value
Anthropometric measurements
Body weight, kg-3.63 (-4.08 to -3.18)-1.29 (-1.81 to -0.79)< 0.001
Body mass index, kg/m2-1.60 (-1.79 to -1.41)-0.56 (-0.72 to -0.39)< 0.001
Waist circumference, cm-5.57 (-6.05 to -5.09)0.87 (-0.42 to 1.32)< 0.001
Hip circumference-4.49 (-5.22 to -3.77)-0.13 (-0.72 to 0.45)< 0.001
Glucose metabolism variables
HbA1c, %-1.19 (-1.36 to -1.01)-1.11 (-1.32 to -0.90)0.511
FPG, mmol/L-1.47 (-1.67 to -1.27)-1.10 (-1.35 to 0.84)0.024
PPG, mmol/L-3.21 (-3.62 to -2.81)-2.82 (-3.32 to -2.32)0.546
Blood pressure and lipid profile
Systolic blood pressure, mmHg-2.11 (-3.97 to -0.25)-0.42 (-2.29 to 1.44)0.207
Diastolic blood pressure, mmHg-1.79 (-3.26 to -0.32)-2.35 (-3.63 to -1.07)0.574
TC, mmol/L-0.48 (-0.62 to 0.34)-0.27 (-0.43 to 0.12)0.103
HDL-C, mmol/L0.07 (-0.03 to 0.11)-0.01 (-0.05 to 0.03)0.012
LDL-C, mmol/L-0.22 (-0.34 to -0.09)-0.07 (-0.20 to 0.07)0.158
NHDL-C, mmol/L-0.55 (-0.69 to -0.41)-0.27 (-0.42 to -0.11)0.021
HDL-C/NHDL-C0.08 (0.06 to 0.10)0.03 (0.01 to 0.05)< 0.001
TG, mmol/L-0.62 (-0.87 to -0.37)-0.90 (-0.42 to -0.07)0.562
Hormones and insulin sensitivity
HOMA-β-0.58 (-10.07 to 8.92)10.09 (-13.30 to 33.49)0.195
I30/G30-0.02 (-2.93 to 2.90)1.43 (-0.09 to 2.95)0.012
FINS, μIU/mL-4.73 (-6.27 to -3.19)-2.88 (-4.80 to -0.95)0.012
AUCinsulin, μIU/L × min-1.47 (-1.86 to -1.07)-0.794 (-1.16 to -0.43)0.092
AUCGLP-1, nmol × min1.41 (1.04 to 1.78)0.65 (1.87 to 1.11)0.002
HOMAIR-2.30 (-2.87 to -1.74)-1.53 (-2.19 to -0.87)0.003
WBISI69.38 (56.59 to 82.17)47.78 (34.63 to 60.93)0.610